In the normal breast, hepatocyte growth factor (HGF) is primarily expressed by stromal cells, and stimulates in a paracrine manner epithelial cells expressing the HGF receptor (Met). In invasive human breast carcinomas, HGF and Met are frequently overexpressed, possibly establishing an autocrine HGF/Met loop that promotes tumour cell invasion. However, the mechanisms leading to autocrine HGF expression in carcinoma cells are not known. We previously demonstrated a cooperative effect between c-Src and Stat3 in the activation of HGF transcription in mammary carcinoma cells. The present report defines a novel Stat3 consensus site at nt À95 in the HGF promoter that is highly conserved in human and mouse, and is required for c-Src and Stat3 to activate HGF transcription in breast epithelial cells. DNA-protein binding studies demonstrated high affinity binding of a Stat3-containing complex to the nt À95 site. Endogenous Stat3 binding to this region of the HGF promoter in carcinoma cells expressing HGF was demonstrated using a chromatin immunoprecipitation assay. In addition, coexpression of Stat3 and activated c-Src caused increased expression of endogenous HGF mRNA and protein and marked cell scattering in breast epithelial cells. Our results delineate a novel c-Src/Stat3-dependent mechanism that regulates HGF promoter activity, and is linked to transformation of mammary epithelial cells.
Introduction
Hepatocyte growth factor (HGF), also known as scatter factor, is a multifunctional cytokine. Through binding to the Met receptor, HGF can induce cell survival, growth, morphogenesis, migration and angiogenesis (Byers et al., 1994) . Both HGF (Schmidt et al., 1995) and Met are essential for normal embryonic development. In the normal breast, HGF is expressed primarily by stromal cells, while epithelial cells express Met but not HGF, thus creating a tightly controlled paracrine mechanism where localized expression of HGF regulates mammary ductal growth and differentiation (Andermarcher et al., 1996) . We (Tuck et al., 1996) and others (Wang et al., 1994; Jin et al., 1996) have shown that, in contrast to what occurs in normal epithelium, HGF and Met are frequently overexpressed in invasive human breast carcinomas as well as many other cancer types (Bussolino et al., 1992; Di Renzo et al., 1992 , 1995a Olivero et al., 1996; Trovato et al., 2004) . This high level of HGF expression has been described as an independent predictor of poor overall survival in patients with breast cancer (Yamashita et al., 1994; Siegfried et al., 1997) . In addition, targeted expression of HGF in mouse mammary epithelium leads to metastatic carcinomas (Gallego et al., 2003) . These observations suggest that establishment of an autocrine HGF loop and sustained activation of the Met-signalling pathway in carcinoma cells may promote their progression to more invasive cancers.
Transcriptional regulation is very important in the restriction of HGF expression to mesenchymal tissues (Liu et al., 1994a; Elliott et al., 2002) . In vivo analyses of HGF promoter regulation in transgenic mice (Bell et al., 1998) , as well as in vitro transient transfection studies have identified important regulatory elements in the proximal promoter region of the HGF gene (Liu et al., 1994a; Plaschke-Schlutter et al., 1995; Jiang and Zarnegar, 1997) . Partial characterization of this region revealed a composite element located at nt À260 to À230 from the transcriptional start site, which binds PPARg1 as well as members of the NF1, AP2 and USF families to regulate HGF transcription. Functional studies show that NF1 and AP2 suppress the activity of the HGF promoter, whereas PPARg1 and USF have activating functions (Jiang et al., 2000a (Jiang et al., , b, 2001 ) . Additional in vitro studies have shown that HGF transcription is positively regulated by oestrogen and dexamethasone, and is inhibited by transforming growth factor-b (TGF-b) (Liu et al., 1994b) . A negative regulatory site at nt À16 to þ 4 has also been identified as being required for suppression of HGF transcription in normal epithelial cells (Liu et al., 1994a) . The mechanisms leading to aberrant HGF expression observed in invasive carcinomas are not known.
Increased activation of two proto-oncogenes, c-Src and Stat3, is associated with many epithelial cancers and is linked to the expression of a number of growth factors such as vascular endothelial growth factor (Mukhopadhyay et al., 1995; Niu et al., 2002) and HGF (Hung and Elliott, 2001; Klosek et al., 2004; Trovato et al., 2004) . In addition, Stat3 is activated through Tyr705 phosphorylation by c-Src (Yu et al., 1995; Turkson et al., 1998) , and Ser727 phosphorylation by the Ras/Rac1/p38-and Jnk-signalling pathways (Turkson et al., 1999) . In support of a role of the c-Src/Stat3 pathway in mammary tumourigenesis, we previously demonstrated a cooperative effect of c-Src and Stat3 on HGF transcription in the murine mammary carcinoma cell line SP1 (Hung and Elliott, 2001 ) which secretes HGF and expresses tyrosinephosphorylated Met (Rahimi et al., 1996) . We further identified a c-Src/Stat3-responsive region in the mouse HGF promoter, localized between nt À254 and À70 from the transcriptional start site (Hung and Elliott, 2001) . Likewise, the human HGF gene was recently shown in melanoma cells to be regulated by leukaemia inhibitory factor (LIF) through a Stat3-binding element (Tomida and Saito, 2004) . Since both c-Src and Stat3 were already known to function as downstream effectors of the HGF/Met-signalling pathway (Boccaccio et al., 1998; Rahimi et al., 1998) , the observation that these molecules can cooperatively stimulate transcription of their own activator provides a novel molecular basis for the HGF autocrine loop previously described in mammary carcinoma cells (Rahimi et al., 1996) .
In the present study, we examined the mechanism of c-Src-dependent Stat3 regulation of HGF transcription and of the transformed phenotype of mammary epithelial cells. Stable coexpression of activated c-Src and Stat3 caused increased HGF transcription and HGF protein expression, concomitant with marked cell scattering in breast epithelial cells. A putative Stat3 site at nt À95 was identified, as defined by the palindromic structure 5 0 -TTCCC G / A G / T AA-3 0 , which has been shown to selectively bind to protein complexes containing Stat3 (Horvath et al., 1995; Seidel et al., 1995) . Using a mutational approach, we demonstrated that the À95 consensus site is required for the observed cooperative effect of c-Src and Stat3 in regulating HGF transcription. DNA-protein binding studies further demonstrated that this site has high affinity for a Stat3-containing complex. These results identify a novel Src/Stat3-dependent mechanism of HGF promoter activation, which could define a new level of tumour specificity associated with the formation of autocrine HGF loops in invasive breast cancer.
Results
Overexpression of both activated c-Src and Stat3 in mammary epithelial cells causes increased phosphorylation of Stat3 Tyr705 and promotes cell scattering We previously demonstrated cooperativity of c-Src and Stat3 in the regulation of HGF transcription in mouse mammary epithelial and carcinoma cell lines (Hung and Elliott, 2001 ). This finding prompted us to determine the effect of c-Src-dependent activation of Stat3 on cell scattering in epithelial cells. A non-neoplastic mouse mammary epithelial cell line, HC11, was stably transfected with an activated c-Src mutant (clone C11), or FLAG-tagged Stat3 (clone C20), or activated c-Src and Stat3 (clone C20/C2). Expression of the corresponding activated c-Src and Stat3 proteins was confirmed by Western blotting analysis ( Figure 1a ). Wild-type (wt) HC11 cells, or cells expressing Stat3 or activated c-Src alone, grew in rounded cell islets with no scattering or filopodia extensions detected (Figure 1c-h ). However, marked filopodia extensions and scattering was observed in cells expressing both activated c-Src and Stat3 (Figure 1i and j) . Expression of activated c-Src alone, but not Stat3, caused marginal cell spreading with no scattering (Figure 1e and f). Thus activated c-Src acts cooperatively with Stat3 to induce cell scattering in nonneoplastic epithelial cells.
To determine the status of c-Src-dependent activation of Stat3 in the above cell lines, we measured Stat3 Tyr705 phosphorylation, which is induced by c-Src and promotes Stat3 dimerization (Yu et al., 1995; Turkson et al., 1998) . Cells overexpressing both activated c-Src and Stat3 (clone C20/C2) showed a high level of Stat3 Tyr705 phosphorylation, whereas overexpression of activated c-Src or Stat3 alone caused only a partial effect (Figure 2a ). HC11 clones expressing activated c-Src (clones C11 and C20/C2) showed enhanced phosphorylation of c-Src Tyr418 compared to untransfected cells (Figure 2b ), indicating increased autophosphorylation of the kinase domain of c-Src in these cells. In contrast to wt HC11 cells, SP1 carcinoma cells showed a level of endogenous Stat3 Tyr705 phosphorylation similar to that of C20/C2 cells. Thus, overexpression of both activated c-Src and Stat3 results in increased phosphorylation of Stat3 Tyr705 in HC11 cells, correlating with increased cell scattering.
The nt À254 to À70 region of the HGF promoter is required for c-Src/Stat3-induced HGF transcription in epithelial cells The c-Src/Stat3 responsive region of the HGF promoter, located between nt À254 and À70 in relation to the start of transcription site, has been shown to be required for the observed increase in HGF transcription in response to activated c-Src and Stat3 in the carcinoma cell line SP1 (Hung and Elliott, 2001) . To assess the role that this region plays in the response of non-neoplastic cells to c-Src and Stat3, the mammary epithelial cell line HC11 was co-transfected with reporter constructs containing various deletions of the HGF promoter linked to the firefly luciferase gene (Hung and Elliott, 2001) , and a combination of vectors expressing Stat3 or the activated form of c-Src (Figure 3 ). Neither the expression of c-Src nor Stat3 alone produced a significant effect on HGF transcription, however, their combined expression resulted in a strong induction of HGF promoter activity in the À274, À538 and À2674 HGF-Luc reporter constructs. Furthermore, deletion mutants of the HGF promoter lacking the nt À254 to À70 region showed no response to overexpression of c-Src and Stat3, similar to what has been described in SP1 carcinoma cells (Hung and Elliott, 2001 ). These results indicate that the nt À254 to À70 region of the HGF promoter is required for the observed increase in HGF transcription in response to c-Src and Stat3 in epithelial cells.
c-Src/Stat3 responsiveness of the HGF promoter maps to the nt À105 to À91 region Examination of the c-Src/Stat3-responsive region of the HGF promoter revealed three putative Stat3-binding consensus sites at nt À149, À110 and À95. To determine the possible role that these sites play in the observed HGF promoter activity, the transcriptional activities of truncated forms of the HGF luciferase reporter lacking only the À149 site (À144 HGF-Luc), both À149 and À110 sites (À105 HGF-Luc), or all three Stat3-binding sites (À91 HGF-Luc), were compared to that of the previously described À274 HGF-Luc and À70 HGFLuc constructs (Figure 4 ). Each reporter construct was transfected into HC11 cells alone, or in combination with activated c-Src and Stat3 plasmids. Expression of activated c-Src and Stat3 induced activation of À274 HGF-Luc, À144 HGF-Luc and À105 HGF-Luc, but no increase in the À91 HGF-Luc or À70 HGF-Luc transfected cells was observed. The À105 HGF-Luc construct lacks over 80% of the originally identified c-Src/Stat3 responsive region (nt À254 to À70), including two of the consensus Stat3-binding sites, À149 and À110, yet this construct still retains the ability to be trans-activated. Although the À274 HGF-Luc response was significantly greater than that of À105 and À144 HGF-Luc, we do not know if these differences are biological relevant. Interestingly, promoter activity was completely abolished when an additional 15 base pairs were deleted (compare À105 HGF-luc to À95 HGF-luc). Similar results were obtained when the same deletion mutant HGF reporter plasmids were expressed in SP1 cells (data not shown). Together, these results further narrow the sequence that is required for HGF responsiveness to c-Src and Stat3, and strongly suggest that of the three sites, only the one located at nt À95 is required for transcriptional activation in response to c-Src and Stat3.
The À95 Stat3 consensus site is required and sufficient for c-Src/Stat3 responsiveness of the HGF promoter in epithelial cells To further analyse the role of each putative Stat3 consensus site, we examined additional upstream sequences (up to nt À538) corresponding to the À538 HGF-Luc construct which exhibits c-Src/Stat3 responsiveness similar to À274 HGF-Luc (Figure 3 ). Reporter plasmids containing the À538 HGF-Luc sequence mutated at each site (À538 À149 M HGF-Luc, À538 À110 M HGF-Luc and À538 À95 M HGF-Luc) were constructed. The mutagenesis strategy involved base substitutions at several positions within the consensus Stat3-binding sequence (5 0 -TTCCC G / A G / T AA-3 0 ), including TT with C or G. Given that the TT element has been shown to play a critical role during Stat3 binding to DNA, such mutations should abolish Stat3-DNA interactions at the sites of interest. Activity of the Novel regulation by Stat3 of HGF transcription EJ Wojcik et al mutants was compared with that of the wt À538 HGFLuc ( Figure 5 ). Each reporter construct was transfected into HC11 cells alone, or combined with Stat3, activated c-Src or a combination of both plasmids. Expression of the c-Src/Stat3 plasmids induced activation of constructs mutated at positions À149 and À110, similar to what was observed in the wt À538 HGF-Luc construct, which has been shown to display expression activity comparable to that of the full-length HGF promoter (Hung and Elliott, 2001 ). In contrast, no such induction was observed in the À538 À95M HGF-Luc-transfected cells. To further confirm the apparent dominance of the À95 Stat3-binding site in regulating HGF promoter activity, an additional mutant was constructed in which all three consensus Stat3-binding sites were mutated (À538 À149 M/À110 M/À95 M HGF-Luc). The triple mutant response to coexpression of activated c-Src and Stat3 was similar to that of À538 À95 M HGF-Luc.
The above results were reproduced in SP1 carcinoma cells which exhibit autocrine HGF expression (Rahimi et al., 1996) and are therefore a physiological system for testing HGF transcription regulation. Coexpression of activated c-Src and Stat3-induced activation of wt À274 HGF-Luc, À274 À149 M HGF-Luc and À274 À110 M HGF-Luc, but not À274 À95 M HGF-Luc or the triple mutant (À274 À149/À110/À95 M HGF-Luc) ( Figure 6 ). A marginal increase in HGF transcription activation by activated c-Src alone was detected with the À149 and À110 M, but not the À95 M mutant constructs, consistent with a basal c-Src responsiveness in SP1 cells as previously reported (Hung and Elliott, 2001 ). These observations support the critical role of the Stat3 consensus site located at position À95 of the HGF promoter that was apparent from the analysis of truncated constructs ( Figure 3 ). The fact that both the À149 M and the À110 M mutant constructs retained their capacity to respond to c-Src/ Stat3 stimulation indicates that the interference with Stat3 binding to these two elements does not prevent activation of HGF transcription in response to Stat3, and suggests that, under these conditions, they do not play a significant role as Stat3-binding sites during the process of HGF transcription activation. Immune complexes were visualized using chemiluminescence. Relative intensity of individual protein bands was measured using densitometry, and quantitation was expressed as the ratio of the phosphorylated protein to the corresponding total protein. Figure 3 The nt À254 to À70 region of the HGF promoter is required for responsiveness of HGF transcription to c-Src and Stat3 in HC11 cells. The À2674 HGF firefly luciferase reporter (À2674 HGF-Luc), or reporter constructs containing the indicated deletions of the HGF promoter were transiently co-transfected into HC11 cells with activated c-Src, Stat3, c-Src/Stat3 or an empty vector (control). A Renilla luciferase expression plasmid (pRL-CMV) was co-transfected in each group for normalization to account for differences in transfection efficiency. After 48 h incubation, cells were lysed and luciferase activity for each sample was determined. The results were normalized to the luciferase activity of the À2674 HGF-Luc construct. Values represent mean relative luciferase activity7s.d. of triplicate samples and are representative of two experiments.
A nuclear protein complex exhibits high affinity binding to the À95 consensus site of the HGF promoter Our demonstration of high levels of Stat3 Tyr705 phosphorylation in HC11 cells expressing activated c-Src and Stat3 compared to wt HC11 cells (Figure 2 ) indicates strong expression of the activated form of Stat3, which should have the capacity of binding to DNA. Electrophoretic mobility shift assays (EMSA) were therefore performed to examine the DNA-binding affinity of nuclear protein extracts from SP1, wt HC11, and C20/C2 cells (stably expressing activated c-Src and Stat3), towards the three different Stat3 consensus sites. To detect protein complex binding, 32 P-labelled oligonucleotide probes with DNA sequences corresponding to the original and the mutated À95 consensus sequence were incubated with nuclear extracts (Figure 7a) . A shift of at least two dominant bands indicative of DNAprotein complexes was observed in all three nuclear extracts, when the wt sequence was used as probe, but not when the mutated sequence was used.
In order to confirm the presence of Stat3 in the observed protein-DNA complexes, nuclear extracts of C20/C2 cells were preincubated with anti-Stat3 antibody prior to the addition of 32 P-labelled oligonucleotides.
Since it is known that other members of the Stat family (Stat1, Stat5a and Stat5b) may also bind to the Stat3 consensus sites, albeit at lower levels, antibodies against specific Stat proteins were used in supershift experiments to determine the composition of the DNA-binding complex. When nuclear extracts from C20/C2 cells were preincubated with antibodies against Stat1, Stat2, Stat3, Stat5a and Stat5b prior to the addition of radiolabelled probe, only the anti-Stat3 antibody produced a supershift band (Figure 7a ). The major complex (lower band) binding to the À95 consensus site showed no supershift indicating that it is not a Stat protein.
We next compared the binding activity of 32 P-labelled oligonucleotides corresponding to the À149, À110 and À95 consensus Stat3-binding sites with nuclear extract from wt HC11 and C20/C2 cells. The assay showed strong binding activity of both the À95 probe and the À110 probe with the nuclear extract from wt HC11 cells, though as expected none of the complexes formed were affected by anti-Stat3 antibody (Figure 7b ). The super- Figure 4 The nt À105 to À91 region of the HGF promoter is required for responsiveness of HGF transcription to c-Src and Stat3 in HC11 cells. The À274 HGF-Luc reporter, or truncated reporter constructs containing the indicated deletions of the HGF promoter, were co-transfected into HC11 cells with activated c-Src, Stat3, c-Src/Stat3 or an empty vector (control). After 48 h incubation, cells were lysed and luciferase activity for each sample was determined and normalized. The results were normalized to the luciferase activity of the À274 HGF-Luc construct. Values represent mean7s.d. of nine samples. Asterisks indicate a significant increase in Stat3/activated c-Src-induced HGF-Luc activity compared to the untreated control groups (P ¼ 0.001*, 0.007**, and 0.0002***, using a two-tailed Fisher's test). The activity of À274 HGF-Luc was significantly greater than that of À144 HGF-Luc (P ¼ 0.002) and À105 HGF-Luc (P ¼ 0.009). shift assay did identify Stat3 in complexes formed between the À95 32 P-oligonucleotide and nuclear extracts from C20/C2 cells, but not with the À110 and À149 probes. This finding is consistent with the higher level of Stat3 activation in C20/C2 cells compared to wt HC11 cells (Figure 2a) .
To assess endogenous Stat3 binding to the HGF promoter, we performed a ChIP assay on SP1 carcinoma cells which express a high basal level of activated Stat3 (Figure 2a) . Antibodies to acetylated histone-3 (Ac-H3), Stat2 and Stat3 were used to immunoprecipitate chromatin from SP1 cells, and primers spanning the HGF promoter were used to detect the presence of this region. The results showed that Ac-H3 is associated with the HGF promoter, as expected for a transcribed gene (Figure 7c) . Furthermore, the ChIP assay indicated that Stat3 but not Stat2 binds to the HGF promoter in these cells, likely activating HGF transcription. This increased level of HGF mRNA expression was similar to that of SP1 carcinoma cells. Both whole cell lysates and conditioned media from C20/C2 and SP1 cells showed a marked increase in HGF a chain (65 kDa), compared to wt HC11 cells (Figure 8b) . A protein corresponding to pro-HGF was also detected in C20/C2 and SP1 cell lysates. A similar result was observed with two additional independent HC11 clones transfected with Stat3 and activated c-Src. Conditioned medium from C20/C2 cells, but not wt HC11 cells, induced scattering of Madin Darby Canine Kidney (MDCK) cells (Figure 8c) . Immunoprecipitation of the conditioned medium with anti-HGF antibody abrogated the scattering effect, confirming the presence of functional HGF (Figure 8d ). Together these results support a positive regulatory role of activated c-Src and Stat3 in the expression of HGF mRNA and functional HGF protein in mammary epithelial cells.
Discussion
The mechanisms by which HGF expression is activated in regions of invasive human breast carcinoma, but is normally repressed in non-neoplastic epithelium, have not been defined (Elliott et al., 2002) . Our laboratory previously demonstrated that activated c-Src and Stat3 can act cooperatively to induce HGF transcription in mammary epithelial cells and that a region in the HGF promoter, localized between nt À254 and nt À70 from Figure 8 Effect of activated c-Src and Stat3 on endogenous HGF transcription, protein expression and cell scattering. (a) mRNA was isolated from SP1, HC11 and C20/C2 cells, and then subjected to semiquantitative RT-PCR using primers for HGF and ribosomal RNA. Another housekeeping gene (TATA-binding protein) gave similar results using real-time PCR (data not shown). PCR products were resolved on 1.5% agarose gels (upper panel), and the mean ratio7s.d. of three cycle numbers in the linear titration range was calculated (lower panel). (b) HC11, C20/C2 and SP1 cells were cultured under serum-free conditions for 48 h, and conditioned media or whole cell lysates were collected. Samples were subjected to 10% reducing SDS-PAGE and Western blotting with anti-HGF antibody (which detects pro-HGF and HGF a chain) was performed as described in Materials and methods. Human recombinant HGF yielded bands corresponding to pro-HGF and HGF a chain which consistently migrated at a slightly lower molecular size compared to endogenous HGF. Two additional HC11 clones expressing activated c-Src and Stat3 yielded similar results (data not shown). Novel regulation by Stat3 of HGF transcription EJ Wojcik et al the transcriptional start site, is required for c-Src/Stat3-induced HGF transcription in mammary carcinoma cells (Hung and Elliott, 2001 ). In the present study, we have identified a novel Stat3 site at nt À95 of the HGF promoter which is required for c-Src/Stat3-induced activation of HGF transcription in epithelial cells. Binding of Stat3 to the nt À95 site of c-Src/Stat3-induced cells was demonstrated using EMSA. In contrast, mutations at two putative Stat3 consensus sites at nt À149 and nt À110 had no detectable effect on c-Src/Stat3-induced HGF promoter activation. Using a ChIP assay, we demonstrated binding of Stat3 to the same region of the endogenous HGF promoter in SP1 carcinoma cells which exhibit HGF expression. We have further shown that the observed activation of HGF transcription is linked to increased expression of endogenous HGF mRNA and protein. These observations suggest that the lack of c-Src kinase activity and the low level of Stat3 activation may be responsible for restricting HGF transcription in epithelial cells of the breast. Together, these results define a novel regulatory site on the mouse HGF promoter, and establish a direct role for c-Src/Stat3 in HGF-mediated tumourigenesis. Since there is 99% identity among the mouse, rat and human HGF promoter sequences between nucleotides À150 and þ 1, and the regulatory site described here is completely conserved among these species (Liu et al., 1994b) , we predict that the regulation of HGF expression by Stat3 through the À95 consensus site is also conserved in human cells. This contention is supported by the recent demonstration of a Stat3 consensus site at nt À99/À91 required for human HGF promoter activation with LIF (Tomida and Saito, 2004) .
The above experiments also identified a protein-DNA complex at the À95 site that does not react with antiStat3 antibodies in supershift assays. Additional supershift studies, using antibodies against specific Stat proteins, excluded Stat1, Stat2, Stat5a and Stat5b as components of these protein-DNA complexes. Tests for Stat4 and Stat6 were not performed, but it is unlikely that these are involved in this phenomenon since they are normally not present or active in mammary tissue (Watson, 2001 ). The observed protein-DNA interaction was found to be very specific using competition assays (data not shown), and the À95 point mutation affects both complexes; these results suggest that the observed non-Stat3 molecular complex may somehow be involved in regulating HGF transcription at the À95 site, possibly by repressing its activity. Further studies will determine how these molecules interact with c-Src/Stat3 in HGF transcription regulation.
Our results show that overexpression of activated c-Src and Stat3 in HC11 (C20/C2) epithelial cells was directly linked to increased expression of endogenous HGF mRNA and pro-HGF protein. Interestingly, the dominant form of secreted HGF in these cells was the precursor chain (85 kDa), although some cleaved a chain (65 kDa) was detected in the whole cell lysate. In contrast, SP1 carcinoma cells secreted detectable HGF a chain, as described previously (Rahimi et al., 1996) . Functional HGF activity in the conditioned medium from C20/C2 cells was demonstrated using a scatter assay, indicating a limited capacity of these cells to process their own HGF. C20/C2 cells also showed a marked increase in scatter phenotype characteristic of epithelial-mesenchymal transition, compared to wt HC11 cells or cells expressing Stat3 or c-Src alone. Thus, acquired autocrine HGF expression may be a key transforming event following overexpression of activated c-Src and Stat3 in HC11 epithelial cells.
Our observations underline the critical dominant role that overexpression of c-Src and Stat3 plays in activation of HGF transcription, while revealing a possible control mechanism that restricts the overexpression of HGF in response to Stat3 in non-neoplastic cells. As shown by the transcriptional studies, HC11 cells must overexpress Stat3 to exhibit increased HGF transcription. Since basal c-Src activity in HC11 cells is low, the overexpressed Stat3 requires coexpression of activated c-Src most likely in order to become fully phosphorylated at Tyr705. Phosphorylation at Ser727 via serine/ threonine kinases through Ras/Rac1 and p38/Jnk pathways downstream of c-Src (Turkson et al., 1999) may also be involved in activation of Stat3 by c-Src. In contrast, high-level phosphorylation of Stat3 Tyr705 occurs spontaneously in SP1 carcinoma cells which normally express high endogenous levels of Stat3 and active c-Src; this characteristic could account for autocrine HGF expression in these cells (Hung and Elliott, 2001 ). Future studies with site-specific Stat3 mutants will assess the role of Y705 and S727 phosphorylation in autocrine HGF expression in carcinoma cells.
It should be noted that there are multiple mechanisms of Stat3 activation, which could differentially affect Stat3 transcriptional regulation and function. For example, we have recently shown that cell-cell adhesion induces c-Src-independent activation of Stat3 in nonneoplastic and neoplastic breast epithelial cells (Vultur et al., 2004) . Stat3 activation can also be regulated independently of phosphorylation, through acetylation/ deacetylation (Braunstein et al., 2003; Yuan et al., 2005) or overexpression of unphosphorylated forms of Stat3 (Yang et al., 2005) . Furthermore, fibroblasts expressing an activated mutant of Stat3 or v-Src exhibit differential gene expression profiles early after oncogenic transformation (Paz et al., 2004) . Interestingly Dolled-Filhart et al. (2003) have recently shown that Tyr705 phosphorylatyion of Stat3 correlates with better overall survival in lymph node-negative breast cancer cases (n ¼ 346). It is therefore possible that the mode of Stat3 activation (e.g. Src independent versus Src dependent) is critical in determining a morphogenic or tumourigenic phenotype.
The present study shows that c-Src and Stat3 can act cooperatively as upstream regulators of HGF expression, resulting in establishment of an HGF autocrine loop, signal amplification, and an invasive phenotype. This model suggests a novel mechanism by which c-Src regulates a shift of Stat3 function towards an oncogenic phenotype. In this system, Stat3 is activated by c-Src through phosphorylation of Tyr705, although concomitant phosphorylation of Ser727 of Stat3 (Turkson et al., 1999) is most likely required for optimal Stat3 activity. Both c-Src and Stat3 are also critical downstream effectors of Met in HGF-mediated tumourigenesis (Boccaccio et al., 1998; Zhang et al., 2002) ; thus a positive regulatory feedback loop is established. Since c-Src/Stat3 are constitutively activated in a large proportion of human carcinomas, Stat3-dependent HGF transcription may be primarily associated with the carcinoma phenotype. Furthermore, this mechanism may be distinct from that regulating HGF expression through oestrogen receptor/COUP-TF, IL-6 receptor, and TGF-b inhibitory binding protein in non-neoplastic cells (reviewed in Elliott et al., 2002) . The c-Src/Stat3-signalling pathway may therefore be an effective target (Darnell, 2002) for disruption of autocrine HGF loops in breast cancer and abrogation of metastasis.
Materials and methods

Cell culture
The mouse mammary epithelial cell line HC11 was maintained in RPMI 1640 medium (Invitrogent, Burlington, ON, Canada) supplemented with 10% fetal bovine serum (FBS) (Invitrogent), 5 mg/ml insulin and 10 ng/ml epidermal growth factor (Ball et al., 1988) . The SP1 tumour cell line is derived from a spontaneous poorly metastatic murine mammary intraductal adenocarcinoma and its characterization has been described previously (Rahimi et al., 1996 (Rahimi et al., , 1998 . SP1 cells were maintained in DMEM medium (Invitrogent) supplemented with 7% FBS. For some experiments, conditioned media were collected following 48 h incubation of cells (60% confluence) in serum-free medium (DMEM), and were clarified by centrifugation at 13 000 g. Oligonucleotides used for electrophoretic mobility shift assay
Antibodies
Oligonucleotides used for ChIP assay HGF promoter F: 5 0 -AGCTGGGATCTGTTGCTTGT-3 0 ; HGF promoter R: 5 0 -TGCGATGAGCTAAGTTTGTTG-3 0 .
Mutagenesis and cloning
The À70, À274, À538, À2674, À538 D À274/À70 and À2674 D À274/À70 HGF-Luc reporter constructs ( Figure 3 ) were made as previously described (Hung and Elliott, 2001 ). Mutants of the HGF promoter were constructed by two rounds of PCR mutagenesis, using the À2674 HGF-Luc construct (Hung and Elliott, 2001) as template. The HGF À95 minus primer was used with the HGF 5 0 primer to generate fragment A, whereas primers HGF 3 0 and HGF À95 plus were used to generate fragment B. Amplification was carried out using Vent polymerase (New England Biolabs, Ipswich, MA, USA) in an Eppendorf MicroCycler for 34 cycles. The generated fragments were purified from a 1% agarose gel and they were both used as template for one reaction in the absence of primers followed by addition of HGF 5 0 and HGF 3 0 primers and 30 cycles amplification. The generated DNA fragment, the À95 mutant, contained a XhoI restriction site at its 5 0 end and a HindIII restriction site at its 3 0 end introduced by the HGF 5 0 and HGF 3 0 primers respectively, along with a mutation at nucleotides corresponding to positions À95 to À90 of the HGF promoter.
The À149 and À110 mutants were constructed following the same procedure, using HGF À149 plus and minus or HGF À110 plus and minus primers, respectively. The triple mutant (À149, À110 and À95) was constructed by using the À149 mutant as template for the HGF 5 0 and HGF À110 minus primers, and the À95 mutant as template for the HGF 3 0 and HGF À110 plus TM primers during the first round of PCR. The introduced mutations are listed in Figure 5b .
The À91 truncation mutant was created using HGF À91 and HGF 3 0 primers and À2674 HGF-Luc as template. A wt fragment was also generated by using À2674 HGF-Luc as template, HGF 5 0 and HGF 3 0 primers and the same PCR conditions as those used for construction of the À91 mutant.
Plasmids were created by inserting the corresponding PCR fragments into the pGL2-basic vector using standard techniques (Promega, Nepean, ON, Canada). The À538 À149 M HGF-Luc, À538 À110 M HGF-Luc, À538 À95 M HGF-Luc and À538 À149/À110/À95 M HGF-Luc constructs were generated by replacing the fragment contained between PvuII and AgeI restriction sites of the 0.5HGF-Luc construct (Hung and Elliott, 2001 ) with the respective mutants generated by PCR and cut with PvuII and AgeI. À144 HGF-Luc was constructed by cutting À274 À149 M HGF-Luc with SmaI, followed by religation. To generate À105 HGF-Luc, the À274 À110 M HGF-Luc construct was digested with PstI/XhoI, treated with T4 DNA Polymerase for end blunting, and religated.
For normalization of transfection efficiency of each sample, pRL-CMV vector (Promega), which provides constitutive expression of the Renilla luciferase, was used.
Cell transfection and luciferase assay All transfections were carried out with the LipofectAMINE Plust system (Invitrogent) according to manufacturer's instructions. HC11 cells were seeded in a six-well plate (1 Â 10 5 cells/well), incubated overnight in complete growth medium and transfected with 1.2 mg of reporter plasmid, 0.2 mg of control reporter (pRL-CMV), and up to 0.6 mg of expression plasmids (pBABE-Y527FSrc and pRSV-Stat3) as indicated. SP1 cells were seeded in a 24-well plate (1 Â 10 4 cells/well), incubated overnight in complete growth medium and transfected with 0.4 mg of reporter plasmid, 0.1 mg of control reporter and up to 0.3 mg of expression plasmids. In some experiments, stable transfectants of HC11 cells expressing c-Src and Stat3 plasmids were selected in media containing G418 (450 mg/ml) and puromycin (2 mg/ml), respectively.
For luciferase assays, transiently transfected cells were lysed after 48 h using the Passive Lysis Buffer (Promega) and the Dual-Luciferaset Reporter assay was performed according to manufacturer's instructions (Promega) using an EG&G Berthold microplate luminometer. The Firefly luciferase activity was normalized to the corresponding CMV-Renilla luciferase activity for each well, and triplicate values for each construct were averaged. The results for each experiment were normalized to the luciferase activity of the full-length HGF-Luc construct used as positive control. Normalized results from repeated experiments were pooled, and expressed as mean7s.d. The number of samples indicated in the figure legends represents the total number of wells transfected in two to three separate experiments.
Nuclear extract preparation Cells were cultured to 80% confluency on 10 cm tissue culture plates, harvested and washed with PBS. The washed cell pellet was resuspended in 5 ml of Cell Lysis Buffer (10 mM HEPES, 15 mM KCl, 2 mM EDTA, 0.5 mM spermidine, 0.15 mM spermine, 0.5% Igepal, 1% dry low-fat milk, 1% trasylol, 1 mM DTT, 0.1 mM phenylmethylsulphonyl fluoride, 1 mg/ml Leu-Pep) and incubated on ice for 5 min. The nuclei were isolated by spinning the cell suspension through a sucrose cushion, and nuclear proteins were extracted, as described previously (Atlas et al., 2000) . The supernatant containing nuclear proteins was frozen in aliquots and stored at À701C until used. The protein content of the nuclear extract was determined using a Micro BCA protein assay (Pierce, Rockford, IL, USA) following manufacturer's instructions.
Probe labelling and eletrophoretic mobility shift assay Complementary oligonucleotides were annealed by boiling together 50 mg of each oligonucleotide for 10 min and then cooling slowly to room temperature. DNA was then precipitated in ethanol, dried and resuspended in TEN 50 (TE pH 7.5, 50 mM NaCl) to a final concentration of 100 ng/ml. The labelling reaction was carried out by incubating 200 ng of annealed oligonucleotides with 5 U of Klenow enzyme, 1 Â Medium Salt Buffer (10 mM Tris-HCl, 10 mM MgCl 2 , 50 mM NaCl, 1 mM DTT, pH 7.9), 5 mM dTTP, 5 mM dCTP, 5 mM dGTP and 20 mCi a 32 P dATP (10.0 mCi/ml) for 20 min at room temperature. The reaction was chased with 5 mM dATP for 10 min. The unincorporated isotope was removed by passing the solution through a G50 column. The binding reaction for EMSA was performed by incubating the nuclear extract with 1 mg poly (dI-dC), 1 Â Bandshift Binding Buffer (10 mM HEPES, 20 mM KCl, 1.5 mM MgCl 2 , 2% Ficoll, 5 mM DTT), 10 ml BSA and 1 ng of 32 P-labelled probe on ice for 20 min. A 6% acrylamide gel was pre-run in 0.25 Â TBE for 30 min at 100 V; the samples were then loaded and electrophoresis was carried out at 150 V for 2.5 h at 41C. The gel was fixed in 7% acetic acid, 40% ethanol for 20 min, vacuum dried on 3 mM Watmann paper and exposed to autoradiograph and PhosphorImager screen for analysis. For supershift experiments, nuclear extracts were incubated with 1 mg of the indicated antibody for 30 min on ice, prior to the binding reaction.
RT-PCR
Cells were plated at 3 Â 10 6 cells per dish. RNA was isolated using the RNeasy kit (Qiagen, Mississauga, ON, Canada) based on the manufacturer's protocol. RNA on the RNeasy column was subjected to DNase treatment using the RNasefree DNase I set (Qiagen) to remove DNA contamination. mRNA was eluted from the RNeasy column using RNase-free water. Total cellular RNA was used in a reverse transcription reaction using Superscript III reverse transcriptase (Invitrogent). Total RNA (5 mg) was pooled with pd(N 6 ) and preheated at 701C for 10 min. The reaction mix (10 Â RT reaction buffer, Superscript III, 40 U of RNase inhibitor and 10 mM dNTP in RNase-free water) was then added to the preheated RNA/pd(N 6 ) mix and the RT reaction was performed using the following conditions to synthesize cDNA: 251C for 15 min, 421C for 30 min, 481C for 20 min and 701C for 15 min. In all, 2 ml of the RT product was PCR-amplified using a 941C 'hot start' for 4 min, followed by 12-35 cycles at 941C for 60 s, 581C for 60 s and 721C for 60 s. PCR amplification was performed using Taq polymerase (New England Biolabs, Pickering, ON, Canada) and primers for HGF (forward: TTC CCA GCT GGT CTA TGG TC, reverse: TGG TGC TGA CTG CAT TTC TC) and 18S rRNA (forward: AAA CGG CTA CCA CAT CCA AG, reverse: CCT CCA ATG GAT CCT CGT TA). The HGF and 18S rRNA PCR products (237, 155 bp, respectively) were resolved on a 1.5% agarose gel. Densitometry was performed using CorelDraw Photo-Paint V12 as a product of band intensity and area and the values were normalized to the background intensity on the gel. Results were calculated for three separate cycles within the linear amplification range as a mean ratio of HGF (signal) to 18S rRNA (control)7s.d.
Chromatin immunoprecipitation (ChIP)
Chromatin preparation from SP1 cells was carried out using a ChIP assay kit according to manufacturer's instructions (Upstate Cell Signalling Solutions, Lake Placid, NT, Canada) with the following modifications: The formaldehyde crosslinking was terminated by the addition of 10 ml of 0.25 M glycine to each 100 mm plate of cells. The chromatin was precleared by the addition of 13 ml of rabbit preimmune serum per 1 Â 10 6 cells, followed by incubation with protein A agarose beads for 2 h. For collection of the immune complexes, additional blocking of the beads involved the addition of 20 mg of BSA and 20 mg of tRNA to 60 ml of beads, followed by a 2 h incubation with the chromatin/immune complexes. Assays were carried out using antibodies to acetylated H3 (Ac-H3), Stat2, Stat3, rabbit preimmune serum, and no antibody. Immunoprecipitated chromatin was amplified by PCR using primers (listed above) which spanned a region of the HGF promoter from nt À39 to nt À195, corresponding to a product size of 154 bp.
Indirect immunofluorescence
Cells were plated overnight on cover slips, rinsed three times in prewarmed PBS with 0.1 mM CaCl 2 and 0.1 mM MgCl 2 , and fixed for 20 min in 3% paraformaldehyde in PBS. Cells were permeablized by incubation for 5 min in 0.2% Triton X-100 in PBS, rinsed three times, and incubated for 10 min in 50 mM NH 4 Cl in PBS. Cells were incubated with anti-chicken c-Src antibody for 45 min, washed three times in PBS, and incubated with the appropriate secondary antibody. All antibody concentrations were predetermined to yield optimal signal noise ratios. Preparations were observed using a Zeiss Axiovert inverted microscope in the Protein Discovery and Function Facility at Queen's University. Image acquisitions were processed using Adobe Photoshop software.
Western blotting
Cells were grown to confluence, rinsed with PBS, and lysed in a RIPA buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 10 mM EGTA, 1% NP-40, 0.1% SDS, 1 mM Na 3 VO 4, 50 mM NaF, 2 mg/ml aprotinin, 2 mg/ml leupetin, and 1 mM phenylmethylsulfonyl fluoride. Lysates were centrifuged for 10 min at 14 000 r.p.m. in an IEC/Micromax centrifuge, and supernatants were subjected to protein determination using a bicinchoninic acid protein assay (Pierce, Rockford, IL, USA). Equal protein amounts of each cell lysate were subjected to 8% SDS-PAGE under reducing conditions (with 2.5% b-2 mercaptoethanol), and transferred to PVDF membranes. Separate membranes were probed with the indicated primary antibodies. Immune complexes were detected using horseradish peroxidase (HRP)-labelled donkey anti-rabbit or antimouse IgG (Amersham Biosciences, Baie d'Urfe´, QC, Canada) or HRP-labelled streptavidin (Sigma Aldrich) followed by chemiluminescence (Northern Lightning TM Perkin Elmer Life Sciences Inc., Woodbridge, ON, Canada). To quantitate protein phosphorylation, the relative intensity of individual protein bands was measured using densitometry, and expressed as the ratio of the phosphorylated protein to the corresponding total protein.
Scatter assay Conditioned media were tested in a scatter assay with MDCK epithelial cell line as described previously (Rahimi et al., 1996) . Conditioned media were added to 24-well tissue culture plates with 5 Â 10 4 MDCK cells per well. After 36-48 h, scatter morphology was assessed and representative images where photographed using phase contrast microscopy. Controls included cells incubated with recombinant HGF (10 ng/ml) and serum-free medium alone. To test for HGF-dependent effects, conditioned media were immunoprecipitated overnight with rabbit anti-HGF antibody (#SC749, Santa Cruz Biotechnology Inc.) or nonimmune IgG (control) and protein A sepharose beads (Amersham Biosciences). Conditioned media were subjected to SDS-PAGE and Western blotting as described above to confirm depletion of HGF following treatment with anti-HGF antibody compared to nonimmune IgG.
